Lululemon's stock is down 44% despite strong cash flow & 60% margins. The market overreacted to a US slowdown, ignoring international growth & a $1B buyback. Activist pressure from founder Chip Wilson could unlock value.

Vor Biopharma executed a reverse split, insider selling, and major capital raises. This crushed the stock price but secured $450M cash, resetting the company for institutional investors.

Target Hospitality (TH) pivots from oil to AI infrastructure, securing a $550M+ contract to house data center workers, driving a major stock surge.

Wave Life Sciences' stock crashed 50% on obesity drug data. But the drug targets toxic fat & preserves muscle, unlike GLP-1s. Insiders are buying, seeing a misunderstood RNA editing pioneer, not a failure.

Smart money orchestrated a VOR Biopharma sell-off, then bought back shares at a 60% discount via a PIPE, recapitalizing the company. Retail was washed out.

Cogent Biosciences' stock surged nearly 500% on strong drug trial data. However, insiders are selling, a large convertible note offering creates a price ceiling, and the stock now prices in perfection, suggesting the rally may be over.

Aeluma's high short interest is a trap. The company has a strong cash position, and recent insider selling represents a cap table rotation, not a failing business. Bears are misreading the data.

Cheesecake Factory's revenue growth masks a 2.2% same-store sales decline. It's funding dividends and buybacks with new debt while insiders sell, signaling deep financial trouble.

Ciena's stock soared 500% on AI hype, but its 440x P/E ratio and exhausted short squeeze signal a dangerous bubble primed for a sharp correction.

Halozyme's stock drop is misunderstood. The "institutional selling" is an accounting change, not a real exit. Insider sales are pre-planned for taxes. The CEO's new pay package requires the stock to hit $115 to fully vest, showing strong board confidence.

Madrigal Pharmaceuticals (MDGL) is poised for a major short squeeze. With 24% of shares short, bears are misreading the data. The company has neutralized the GLP-1 threat via a licensing deal, extended key patents to 2045, and is hitting revenue milestones.

ACADIA's stock is mispriced. It's a profitable $1B+ revenue company with $820M cash, yet trades low due to misunderstood tax-related insider sales and temporary IRA charges. The market ignores its strong financials and pipeline.

ADMA's panic selloff is a contrarian opportunity. The CEO's stock sales and a misunderstood $125M share buyback triggered the crash, but the company's fundamentals remain strong.

Molina Healthcare's stock plunged after a tough Q4 2025 and weak 2026 guidance. However, the sell-off is a mispricing. Management is taking aggressive, one-time actions to exit a troubled business and reset for a future margin recovery, creating a contrarian opportunity.

Theravance Biopharma's stock crashed after a Phase 3 trial failure. However, the company now has a strong cash position, zero debt, and profitable assets like YUPELRI and Trelegy royalties. With R&D costs slashed, it's transitioning to a cash-generating business at a deeply undervalued price.

Aurinia's stock surge is just the start. The biotech is now a cash-generating machine with a cheap valuation. A recent boardroom coup by activist Kevin Tang signals a likely sale or major strategic shift is imminent.

Wall Street's short-term focus has mispriced ARS Pharmaceuticals (SPRY). The market is fixated on launch losses, ignoring its strong revenue start, ample cash, and potential to disrupt the multi-billion dollar epinephrine market.

Mesoblast's $14 stock price is a mispriced opportunity. A key insider bought out toxic debt, provided cheap financing, and invested $16M in shares. The company is now commercial with strong revenue growth, not a speculative cash burn.

AAOI's stock surged on AI hype, hitting a $6.5B valuation. However, the company is still losing money despite record revenue, and insiders are aggressively selling their shares.

Apogee's stock soared 96% on strong trial data, valuing it at $6.5B. However, insiders are aggressively selling shares, signaling major risk for the pre-revenue biotech.